590.87
+5.37(+0.92%)
Currency In USD
| Previous Close | 585.5 |
| Open | 589.52 |
| Day High | 590.87 |
| Day Low | 588.92 |
| 52-Week High | 1,165.85 |
| 52-Week Low | 476.49 |
| Volume | 10,585 |
| Average Volume | 982,612 |
| Market Cap | 61.55B |
| PE | 14.89 |
| EPS | 39.68 |
| Moving Average 50 Days | 565.94 |
| Moving Average 200 Days | 619.39 |
| Change | 5.37 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,073.61 as of September 18, 2025 at a share price of $590.87. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,064.17 as of September 18, 2025 at a share price of $590.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
GlobeNewswire Inc.
Yesterday at 1:30 PM GMT
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss Numeric improvements in metabolic a
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both number and volume of abnormal bone
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
GlobeNewswire Inc.
Sep 08, 2025 10:30 AM GMT
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 development TARRYTOWN, N.Y., Sept